Our study revealed that pulmonary NMC patients with somatic mutation in PI3K/AKT pathway had significantly worse overall survival, providing a genetic basis for the efficacy of PI3K/AKT pathway inhibitor. Here, AKT1 is linked to nut midline carcinoma.